Global Antihistamine Drugs Market

Antihistamine Drugs Comprehensive Study by Type (Sedating (Brompheniramine, Chlorpheniramine, Diphenhydramine, Doxylamine, Carbinoxamine, and Others), Non-Sedating Antihistamines (Fexofenadine, Loratadine, Loratadine Odt, and Others)), End Users (Hospitals, Clinics, Pharmaceutical Companies, Others), Route of Administration (Oral Route, Parenteral Route (Intramuscular, Subcutaneous and Intravenous Route.), Rectal Route), Indication (Allergy, Urticaria, Dermatitis, Others) Players and Region - Global Market Outlook to 2024

Antihistamine Drugs Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Antihistamines are used to treat allergic conditions that result from the release of histamine. Antihistamines market has high growth prospects owing to the increasing geriatric population and rising prevalence of skin allergies. Further, growing healthcare infratstrure in the developing economies and research and development in the healthcare industry expected to drive the demand for antihistamines drugs over the forecasted period.This growth is primarily driven by Growing Prevalence of Skin Allergies and Rising Geriatric Population.

Globally, a noticeable market trend is evident Research and Development in the Healthcare Industry. Major Players, such as Johnson & Johnson Consumer Inc. (United States), Sanofi (France), Bayer AG (Germany), Pfizer (United States), CVS pharmacy (United States), Merck & Co., Inc. (United States), Prestige Brands Holdings, Inc. (United States), Novartis (Switzerland) and Teva Pharmaceutical (Israel) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Market Drivers
  • Growing Prevalence of Skin Allergies
  • Rising Geriatric Population

Market Trend
  • Research and Development in the Healthcare Industry

Restraints
  • Stringent Government Regulations Regarding Medical Drugs
  • Side Effects May Cause Such As Dry Mouth, Dizziness, Nervousness, Decreased Appetite, and Blurred Vision

Opportunities
Technological Advancement in the Healthcare Industry and Growing Healthcare Infrastructure in the Developing Economies
Challenges
Lack of Awareness in the Emerging Economies and Intense Competition among Market Players

AdvanceMarketAnalytics follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization of the Report:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase

Report Objectives / Segmentation Covered

By Type
  • Sedating [Brompheniramine, Chlorpheniramine, Diphenhydramine, Doxylamine, Carbinoxamine, and Others]
  • Non-Sedating Antihistamines [Fexofenadine, Loratadine, Loratadine Odt, and Others]
By End Users
  • Hospitals
  • Clinics
  • Pharmaceutical Companies
  • Others

By Route of Administration
  • Oral Route
  • Parenteral Route [Intramuscular, Subcutaneous and Intravenous Route.]
  • Rectal Route

By Indication
  • Allergy
  • Urticaria
  • Dermatitis
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Prevalence of Skin Allergies
      • 3.2.2. Rising Geriatric Population
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness in the Emerging Economies
      • 3.3.2. Intense Competition among Market Players
    • 3.4. Market Trends
      • 3.4.1. Research and Development in the Healthcare Industry
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Antihistamine Drugs, by Type, End Users, Route of Administration, Indication and Region (value and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Antihistamine Drugs (Value)
      • 5.2.1. Global Antihistamine Drugs by: Type (Value)
        • 5.2.1.1. Sedating [Brompheniramine, Chlorpheniramine, Diphenhydramine, Doxylamine, Carbinoxamine, and Others]
        • 5.2.1.2. Non-Sedating Antihistamines [Fexofenadine, Loratadine, Loratadine Odt, and Others]
      • 5.2.2. Global Antihistamine Drugs by: End Users (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Pharmaceutical Companies
        • 5.2.2.4. Others
      • 5.2.3. Global Antihistamine Drugs by: Route of Administration (Value)
        • 5.2.3.1. Oral Route
        • 5.2.3.2. Parenteral Route [Intramuscular, Subcutaneous and Intravenous Route.]
        • 5.2.3.3. Rectal Route
      • 5.2.4. Global Antihistamine Drugs by: Indication (Value)
        • 5.2.4.1. Allergy
        • 5.2.4.2. Urticaria
        • 5.2.4.3. Dermatitis
        • 5.2.4.4. Others
      • 5.2.5. Global Antihistamine Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Antihistamine Drugs (Price)
      • 5.3.1. Global Antihistamine Drugs by: Type (Price)
  • 6. Antihistamine Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Johnson & Johnson Consumer Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sanofi (France)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bayer AG (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. CVS pharmacy (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Merck & Co., Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Prestige Brands Holdings, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Novartis (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Teva Pharmaceutical (Israel)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Antihistamine Drugs Sale, by Type, End Users, Route of Administration, Indication and Region (value and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Antihistamine Drugs (Value)
      • 7.2.1. Global Antihistamine Drugs by: Type (Value)
        • 7.2.1.1. Sedating [Brompheniramine, Chlorpheniramine, Diphenhydramine, Doxylamine, Carbinoxamine, and Others]
        • 7.2.1.2. Non-Sedating Antihistamines [Fexofenadine, Loratadine, Loratadine Odt, and Others]
      • 7.2.2. Global Antihistamine Drugs by: End Users (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Pharmaceutical Companies
        • 7.2.2.4. Others
      • 7.2.3. Global Antihistamine Drugs by: Route of Administration (Value)
        • 7.2.3.1. Oral Route
        • 7.2.3.2. Parenteral Route [Intramuscular, Subcutaneous and Intravenous Route.]
        • 7.2.3.3. Rectal Route
      • 7.2.4. Global Antihistamine Drugs by: Indication (Value)
        • 7.2.4.1. Allergy
        • 7.2.4.2. Urticaria
        • 7.2.4.3. Dermatitis
        • 7.2.4.4. Others
      • 7.2.5. Global Antihistamine Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Antihistamine Drugs (Price)
      • 7.3.1. Global Antihistamine Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Antihistamine Drugs: by Type(USD Million)
  • Table 2. Antihistamine Drugs Sedating [Brompheniramine, Chlorpheniramine, Diphenhydramine, Doxylamine, Carbinoxamine, and Others] , by Region USD Million (2013-2018)
  • Table 3. Antihistamine Drugs Non-Sedating Antihistamines [Fexofenadine, Loratadine, Loratadine Odt, and Others] , by Region USD Million (2013-2018)
  • Table 4. Antihistamine Drugs: by End Users(USD Million)
  • Table 5. Antihistamine Drugs Hospitals , by Region USD Million (2013-2018)
  • Table 6. Antihistamine Drugs Clinics , by Region USD Million (2013-2018)
  • Table 7. Antihistamine Drugs Pharmaceutical Companies , by Region USD Million (2013-2018)
  • Table 8. Antihistamine Drugs Others , by Region USD Million (2013-2018)
  • Table 9. Antihistamine Drugs: by Route of Administration(USD Million)
  • Table 10. Antihistamine Drugs Oral Route , by Region USD Million (2013-2018)
  • Table 11. Antihistamine Drugs Parenteral Route [Intramuscular, Subcutaneous and Intravenous Route.] , by Region USD Million (2013-2018)
  • Table 12. Antihistamine Drugs Rectal Route , by Region USD Million (2013-2018)
  • Table 13. Antihistamine Drugs: by Indication(USD Million)
  • Table 14. Antihistamine Drugs Allergy , by Region USD Million (2013-2018)
  • Table 15. Antihistamine Drugs Urticaria , by Region USD Million (2013-2018)
  • Table 16. Antihistamine Drugs Dermatitis , by Region USD Million (2013-2018)
  • Table 17. Antihistamine Drugs Others , by Region USD Million (2013-2018)
  • Table 18. South America Antihistamine Drugs, by Country USD Million (2013-2018)
  • Table 19. South America Antihistamine Drugs, by Type USD Million (2013-2018)
  • Table 20. South America Antihistamine Drugs, by End Users USD Million (2013-2018)
  • Table 21. South America Antihistamine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 22. South America Antihistamine Drugs, by Indication USD Million (2013-2018)
  • Table 23. Brazil Antihistamine Drugs, by Type USD Million (2013-2018)
  • Table 24. Brazil Antihistamine Drugs, by End Users USD Million (2013-2018)
  • Table 25. Brazil Antihistamine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 26. Brazil Antihistamine Drugs, by Indication USD Million (2013-2018)
  • Table 27. Argentina Antihistamine Drugs, by Type USD Million (2013-2018)
  • Table 28. Argentina Antihistamine Drugs, by End Users USD Million (2013-2018)
  • Table 29. Argentina Antihistamine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 30. Argentina Antihistamine Drugs, by Indication USD Million (2013-2018)
  • Table 31. Rest of South America Antihistamine Drugs, by Type USD Million (2013-2018)
  • Table 32. Rest of South America Antihistamine Drugs, by End Users USD Million (2013-2018)
  • Table 33. Rest of South America Antihistamine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 34. Rest of South America Antihistamine Drugs, by Indication USD Million (2013-2018)
  • Table 35. Asia Pacific Antihistamine Drugs, by Country USD Million (2013-2018)
  • Table 36. Asia Pacific Antihistamine Drugs, by Type USD Million (2013-2018)
  • Table 37. Asia Pacific Antihistamine Drugs, by End Users USD Million (2013-2018)
  • Table 38. Asia Pacific Antihistamine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 39. Asia Pacific Antihistamine Drugs, by Indication USD Million (2013-2018)
  • Table 40. China Antihistamine Drugs, by Type USD Million (2013-2018)
  • Table 41. China Antihistamine Drugs, by End Users USD Million (2013-2018)
  • Table 42. China Antihistamine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 43. China Antihistamine Drugs, by Indication USD Million (2013-2018)
  • Table 44. Japan Antihistamine Drugs, by Type USD Million (2013-2018)
  • Table 45. Japan Antihistamine Drugs, by End Users USD Million (2013-2018)
  • Table 46. Japan Antihistamine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 47. Japan Antihistamine Drugs, by Indication USD Million (2013-2018)
  • Table 48. India Antihistamine Drugs, by Type USD Million (2013-2018)
  • Table 49. India Antihistamine Drugs, by End Users USD Million (2013-2018)
  • Table 50. India Antihistamine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 51. India Antihistamine Drugs, by Indication USD Million (2013-2018)
  • Table 52. South Korea Antihistamine Drugs, by Type USD Million (2013-2018)
  • Table 53. South Korea Antihistamine Drugs, by End Users USD Million (2013-2018)
  • Table 54. South Korea Antihistamine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 55. South Korea Antihistamine Drugs, by Indication USD Million (2013-2018)
  • Table 56. Taiwan Antihistamine Drugs, by Type USD Million (2013-2018)
  • Table 57. Taiwan Antihistamine Drugs, by End Users USD Million (2013-2018)
  • Table 58. Taiwan Antihistamine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 59. Taiwan Antihistamine Drugs, by Indication USD Million (2013-2018)
  • Table 60. Australia Antihistamine Drugs, by Type USD Million (2013-2018)
  • Table 61. Australia Antihistamine Drugs, by End Users USD Million (2013-2018)
  • Table 62. Australia Antihistamine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 63. Australia Antihistamine Drugs, by Indication USD Million (2013-2018)
  • Table 64. Rest of Asia-Pacific Antihistamine Drugs, by Type USD Million (2013-2018)
  • Table 65. Rest of Asia-Pacific Antihistamine Drugs, by End Users USD Million (2013-2018)
  • Table 66. Rest of Asia-Pacific Antihistamine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 67. Rest of Asia-Pacific Antihistamine Drugs, by Indication USD Million (2013-2018)
  • Table 68. Europe Antihistamine Drugs, by Country USD Million (2013-2018)
  • Table 69. Europe Antihistamine Drugs, by Type USD Million (2013-2018)
  • Table 70. Europe Antihistamine Drugs, by End Users USD Million (2013-2018)
  • Table 71. Europe Antihistamine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 72. Europe Antihistamine Drugs, by Indication USD Million (2013-2018)
  • Table 73. Germany Antihistamine Drugs, by Type USD Million (2013-2018)
  • Table 74. Germany Antihistamine Drugs, by End Users USD Million (2013-2018)
  • Table 75. Germany Antihistamine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 76. Germany Antihistamine Drugs, by Indication USD Million (2013-2018)
  • Table 77. France Antihistamine Drugs, by Type USD Million (2013-2018)
  • Table 78. France Antihistamine Drugs, by End Users USD Million (2013-2018)
  • Table 79. France Antihistamine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 80. France Antihistamine Drugs, by Indication USD Million (2013-2018)
  • Table 81. Italy Antihistamine Drugs, by Type USD Million (2013-2018)
  • Table 82. Italy Antihistamine Drugs, by End Users USD Million (2013-2018)
  • Table 83. Italy Antihistamine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 84. Italy Antihistamine Drugs, by Indication USD Million (2013-2018)
  • Table 85. United Kingdom Antihistamine Drugs, by Type USD Million (2013-2018)
  • Table 86. United Kingdom Antihistamine Drugs, by End Users USD Million (2013-2018)
  • Table 87. United Kingdom Antihistamine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 88. United Kingdom Antihistamine Drugs, by Indication USD Million (2013-2018)
  • Table 89. Netherlands Antihistamine Drugs, by Type USD Million (2013-2018)
  • Table 90. Netherlands Antihistamine Drugs, by End Users USD Million (2013-2018)
  • Table 91. Netherlands Antihistamine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 92. Netherlands Antihistamine Drugs, by Indication USD Million (2013-2018)
  • Table 93. Rest of Europe Antihistamine Drugs, by Type USD Million (2013-2018)
  • Table 94. Rest of Europe Antihistamine Drugs, by End Users USD Million (2013-2018)
  • Table 95. Rest of Europe Antihistamine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 96. Rest of Europe Antihistamine Drugs, by Indication USD Million (2013-2018)
  • Table 97. MEA Antihistamine Drugs, by Country USD Million (2013-2018)
  • Table 98. MEA Antihistamine Drugs, by Type USD Million (2013-2018)
  • Table 99. MEA Antihistamine Drugs, by End Users USD Million (2013-2018)
  • Table 100. MEA Antihistamine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 101. MEA Antihistamine Drugs, by Indication USD Million (2013-2018)
  • Table 102. Middle East Antihistamine Drugs, by Type USD Million (2013-2018)
  • Table 103. Middle East Antihistamine Drugs, by End Users USD Million (2013-2018)
  • Table 104. Middle East Antihistamine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 105. Middle East Antihistamine Drugs, by Indication USD Million (2013-2018)
  • Table 106. Africa Antihistamine Drugs, by Type USD Million (2013-2018)
  • Table 107. Africa Antihistamine Drugs, by End Users USD Million (2013-2018)
  • Table 108. Africa Antihistamine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 109. Africa Antihistamine Drugs, by Indication USD Million (2013-2018)
  • Table 110. North America Antihistamine Drugs, by Country USD Million (2013-2018)
  • Table 111. North America Antihistamine Drugs, by Type USD Million (2013-2018)
  • Table 112. North America Antihistamine Drugs, by End Users USD Million (2013-2018)
  • Table 113. North America Antihistamine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 114. North America Antihistamine Drugs, by Indication USD Million (2013-2018)
  • Table 115. United States Antihistamine Drugs, by Type USD Million (2013-2018)
  • Table 116. United States Antihistamine Drugs, by End Users USD Million (2013-2018)
  • Table 117. United States Antihistamine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 118. United States Antihistamine Drugs, by Indication USD Million (2013-2018)
  • Table 119. Canada Antihistamine Drugs, by Type USD Million (2013-2018)
  • Table 120. Canada Antihistamine Drugs, by End Users USD Million (2013-2018)
  • Table 121. Canada Antihistamine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 122. Canada Antihistamine Drugs, by Indication USD Million (2013-2018)
  • Table 123. Mexico Antihistamine Drugs, by Type USD Million (2013-2018)
  • Table 124. Mexico Antihistamine Drugs, by End Users USD Million (2013-2018)
  • Table 125. Mexico Antihistamine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 126. Mexico Antihistamine Drugs, by Indication USD Million (2013-2018)
  • Table 127. Antihistamine Drugs: by Type(USD/Units)
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Antihistamine Drugs: by Type(USD Million)
  • Table 138. Antihistamine Drugs Sedating [Brompheniramine, Chlorpheniramine, Diphenhydramine, Doxylamine, Carbinoxamine, and Others] , by Region USD Million (2019-2024)
  • Table 139. Antihistamine Drugs Non-Sedating Antihistamines [Fexofenadine, Loratadine, Loratadine Odt, and Others] , by Region USD Million (2019-2024)
  • Table 140. Antihistamine Drugs: by End Users(USD Million)
  • Table 141. Antihistamine Drugs Hospitals , by Region USD Million (2019-2024)
  • Table 142. Antihistamine Drugs Clinics , by Region USD Million (2019-2024)
  • Table 143. Antihistamine Drugs Pharmaceutical Companies , by Region USD Million (2019-2024)
  • Table 144. Antihistamine Drugs Others , by Region USD Million (2019-2024)
  • Table 145. Antihistamine Drugs: by Route of Administration(USD Million)
  • Table 146. Antihistamine Drugs Oral Route , by Region USD Million (2019-2024)
  • Table 147. Antihistamine Drugs Parenteral Route [Intramuscular, Subcutaneous and Intravenous Route.] , by Region USD Million (2019-2024)
  • Table 148. Antihistamine Drugs Rectal Route , by Region USD Million (2019-2024)
  • Table 149. Antihistamine Drugs: by Indication(USD Million)
  • Table 150. Antihistamine Drugs Allergy , by Region USD Million (2019-2024)
  • Table 151. Antihistamine Drugs Urticaria , by Region USD Million (2019-2024)
  • Table 152. Antihistamine Drugs Dermatitis , by Region USD Million (2019-2024)
  • Table 153. Antihistamine Drugs Others , by Region USD Million (2019-2024)
  • Table 154. South America Antihistamine Drugs, by Country USD Million (2019-2024)
  • Table 155. South America Antihistamine Drugs, by Type USD Million (2019-2024)
  • Table 156. South America Antihistamine Drugs, by End Users USD Million (2019-2024)
  • Table 157. South America Antihistamine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 158. South America Antihistamine Drugs, by Indication USD Million (2019-2024)
  • Table 159. Brazil Antihistamine Drugs, by Type USD Million (2019-2024)
  • Table 160. Brazil Antihistamine Drugs, by End Users USD Million (2019-2024)
  • Table 161. Brazil Antihistamine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 162. Brazil Antihistamine Drugs, by Indication USD Million (2019-2024)
  • Table 163. Argentina Antihistamine Drugs, by Type USD Million (2019-2024)
  • Table 164. Argentina Antihistamine Drugs, by End Users USD Million (2019-2024)
  • Table 165. Argentina Antihistamine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 166. Argentina Antihistamine Drugs, by Indication USD Million (2019-2024)
  • Table 167. Rest of South America Antihistamine Drugs, by Type USD Million (2019-2024)
  • Table 168. Rest of South America Antihistamine Drugs, by End Users USD Million (2019-2024)
  • Table 169. Rest of South America Antihistamine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 170. Rest of South America Antihistamine Drugs, by Indication USD Million (2019-2024)
  • Table 171. Asia Pacific Antihistamine Drugs, by Country USD Million (2019-2024)
  • Table 172. Asia Pacific Antihistamine Drugs, by Type USD Million (2019-2024)
  • Table 173. Asia Pacific Antihistamine Drugs, by End Users USD Million (2019-2024)
  • Table 174. Asia Pacific Antihistamine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 175. Asia Pacific Antihistamine Drugs, by Indication USD Million (2019-2024)
  • Table 176. China Antihistamine Drugs, by Type USD Million (2019-2024)
  • Table 177. China Antihistamine Drugs, by End Users USD Million (2019-2024)
  • Table 178. China Antihistamine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 179. China Antihistamine Drugs, by Indication USD Million (2019-2024)
  • Table 180. Japan Antihistamine Drugs, by Type USD Million (2019-2024)
  • Table 181. Japan Antihistamine Drugs, by End Users USD Million (2019-2024)
  • Table 182. Japan Antihistamine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 183. Japan Antihistamine Drugs, by Indication USD Million (2019-2024)
  • Table 184. India Antihistamine Drugs, by Type USD Million (2019-2024)
  • Table 185. India Antihistamine Drugs, by End Users USD Million (2019-2024)
  • Table 186. India Antihistamine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 187. India Antihistamine Drugs, by Indication USD Million (2019-2024)
  • Table 188. South Korea Antihistamine Drugs, by Type USD Million (2019-2024)
  • Table 189. South Korea Antihistamine Drugs, by End Users USD Million (2019-2024)
  • Table 190. South Korea Antihistamine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 191. South Korea Antihistamine Drugs, by Indication USD Million (2019-2024)
  • Table 192. Taiwan Antihistamine Drugs, by Type USD Million (2019-2024)
  • Table 193. Taiwan Antihistamine Drugs, by End Users USD Million (2019-2024)
  • Table 194. Taiwan Antihistamine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 195. Taiwan Antihistamine Drugs, by Indication USD Million (2019-2024)
  • Table 196. Australia Antihistamine Drugs, by Type USD Million (2019-2024)
  • Table 197. Australia Antihistamine Drugs, by End Users USD Million (2019-2024)
  • Table 198. Australia Antihistamine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 199. Australia Antihistamine Drugs, by Indication USD Million (2019-2024)
  • Table 200. Rest of Asia-Pacific Antihistamine Drugs, by Type USD Million (2019-2024)
  • Table 201. Rest of Asia-Pacific Antihistamine Drugs, by End Users USD Million (2019-2024)
  • Table 202. Rest of Asia-Pacific Antihistamine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 203. Rest of Asia-Pacific Antihistamine Drugs, by Indication USD Million (2019-2024)
  • Table 204. Europe Antihistamine Drugs, by Country USD Million (2019-2024)
  • Table 205. Europe Antihistamine Drugs, by Type USD Million (2019-2024)
  • Table 206. Europe Antihistamine Drugs, by End Users USD Million (2019-2024)
  • Table 207. Europe Antihistamine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 208. Europe Antihistamine Drugs, by Indication USD Million (2019-2024)
  • Table 209. Germany Antihistamine Drugs, by Type USD Million (2019-2024)
  • Table 210. Germany Antihistamine Drugs, by End Users USD Million (2019-2024)
  • Table 211. Germany Antihistamine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 212. Germany Antihistamine Drugs, by Indication USD Million (2019-2024)
  • Table 213. France Antihistamine Drugs, by Type USD Million (2019-2024)
  • Table 214. France Antihistamine Drugs, by End Users USD Million (2019-2024)
  • Table 215. France Antihistamine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 216. France Antihistamine Drugs, by Indication USD Million (2019-2024)
  • Table 217. Italy Antihistamine Drugs, by Type USD Million (2019-2024)
  • Table 218. Italy Antihistamine Drugs, by End Users USD Million (2019-2024)
  • Table 219. Italy Antihistamine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 220. Italy Antihistamine Drugs, by Indication USD Million (2019-2024)
  • Table 221. United Kingdom Antihistamine Drugs, by Type USD Million (2019-2024)
  • Table 222. United Kingdom Antihistamine Drugs, by End Users USD Million (2019-2024)
  • Table 223. United Kingdom Antihistamine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 224. United Kingdom Antihistamine Drugs, by Indication USD Million (2019-2024)
  • Table 225. Netherlands Antihistamine Drugs, by Type USD Million (2019-2024)
  • Table 226. Netherlands Antihistamine Drugs, by End Users USD Million (2019-2024)
  • Table 227. Netherlands Antihistamine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 228. Netherlands Antihistamine Drugs, by Indication USD Million (2019-2024)
  • Table 229. Rest of Europe Antihistamine Drugs, by Type USD Million (2019-2024)
  • Table 230. Rest of Europe Antihistamine Drugs, by End Users USD Million (2019-2024)
  • Table 231. Rest of Europe Antihistamine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 232. Rest of Europe Antihistamine Drugs, by Indication USD Million (2019-2024)
  • Table 233. MEA Antihistamine Drugs, by Country USD Million (2019-2024)
  • Table 234. MEA Antihistamine Drugs, by Type USD Million (2019-2024)
  • Table 235. MEA Antihistamine Drugs, by End Users USD Million (2019-2024)
  • Table 236. MEA Antihistamine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 237. MEA Antihistamine Drugs, by Indication USD Million (2019-2024)
  • Table 238. Middle East Antihistamine Drugs, by Type USD Million (2019-2024)
  • Table 239. Middle East Antihistamine Drugs, by End Users USD Million (2019-2024)
  • Table 240. Middle East Antihistamine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 241. Middle East Antihistamine Drugs, by Indication USD Million (2019-2024)
  • Table 242. Africa Antihistamine Drugs, by Type USD Million (2019-2024)
  • Table 243. Africa Antihistamine Drugs, by End Users USD Million (2019-2024)
  • Table 244. Africa Antihistamine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 245. Africa Antihistamine Drugs, by Indication USD Million (2019-2024)
  • Table 246. North America Antihistamine Drugs, by Country USD Million (2019-2024)
  • Table 247. North America Antihistamine Drugs, by Type USD Million (2019-2024)
  • Table 248. North America Antihistamine Drugs, by End Users USD Million (2019-2024)
  • Table 249. North America Antihistamine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 250. North America Antihistamine Drugs, by Indication USD Million (2019-2024)
  • Table 251. United States Antihistamine Drugs, by Type USD Million (2019-2024)
  • Table 252. United States Antihistamine Drugs, by End Users USD Million (2019-2024)
  • Table 253. United States Antihistamine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 254. United States Antihistamine Drugs, by Indication USD Million (2019-2024)
  • Table 255. Canada Antihistamine Drugs, by Type USD Million (2019-2024)
  • Table 256. Canada Antihistamine Drugs, by End Users USD Million (2019-2024)
  • Table 257. Canada Antihistamine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 258. Canada Antihistamine Drugs, by Indication USD Million (2019-2024)
  • Table 259. Mexico Antihistamine Drugs, by Type USD Million (2019-2024)
  • Table 260. Mexico Antihistamine Drugs, by End Users USD Million (2019-2024)
  • Table 261. Mexico Antihistamine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 262. Mexico Antihistamine Drugs, by Indication USD Million (2019-2024)
  • Table 263. Antihistamine Drugs: by Type(USD/Units)
  • Table 264. Research Programs/Design for This Report
  • Table 265. Key Data Information from Secondary Sources
  • Table 266. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Antihistamine Drugs: by Type USD Million (2013-2018)
  • Figure 5. Global Antihistamine Drugs: by End Users USD Million (2013-2018)
  • Figure 6. Global Antihistamine Drugs: by Route of Administration USD Million (2013-2018)
  • Figure 7. Global Antihistamine Drugs: by Indication USD Million (2013-2018)
  • Figure 8. South America Antihistamine Drugs Share (%), by Country
  • Figure 9. Asia Pacific Antihistamine Drugs Share (%), by Country
  • Figure 10. Europe Antihistamine Drugs Share (%), by Country
  • Figure 11. MEA Antihistamine Drugs Share (%), by Country
  • Figure 12. North America Antihistamine Drugs Share (%), by Country
  • Figure 13. Global Antihistamine Drugs: by Type USD/Units (2013-2018)
  • Figure 14. Global Antihistamine Drugs share by Players 2018 (%)
  • Figure 15. Global Antihistamine Drugs share by Players (Top 3) 2018(%)
  • Figure 16. Global Antihistamine Drugs share by Players (Top 5) 2018(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Johnson & Johnson Consumer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Johnson & Johnson Consumer Inc. (United States) Revenue: by Geography 2018
  • Figure 20. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 21. Sanofi (France) Revenue: by Geography 2018
  • Figure 22. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 23. Bayer AG (Germany) Revenue: by Geography 2018
  • Figure 24. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 25. Pfizer (United States) Revenue: by Geography 2018
  • Figure 26. CVS pharmacy (United States) Revenue, Net Income and Gross profit
  • Figure 27. CVS pharmacy (United States) Revenue: by Geography 2018
  • Figure 28. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Merck & Co., Inc. (United States) Revenue: by Geography 2018
  • Figure 30. Prestige Brands Holdings, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Prestige Brands Holdings, Inc. (United States) Revenue: by Geography 2018
  • Figure 32. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 33. Novartis (Switzerland) Revenue: by Geography 2018
  • Figure 34. Teva Pharmaceutical (Israel) Revenue, Net Income and Gross profit
  • Figure 35. Teva Pharmaceutical (Israel) Revenue: by Geography 2018
  • Figure 36. Global Antihistamine Drugs: by Type USD Million (2019-2024)
  • Figure 37. Global Antihistamine Drugs: by End Users USD Million (2019-2024)
  • Figure 38. Global Antihistamine Drugs: by Route of Administration USD Million (2019-2024)
  • Figure 39. Global Antihistamine Drugs: by Indication USD Million (2019-2024)
  • Figure 40. South America Antihistamine Drugs Share (%), by Country
  • Figure 41. Asia Pacific Antihistamine Drugs Share (%), by Country
  • Figure 42. Europe Antihistamine Drugs Share (%), by Country
  • Figure 43. MEA Antihistamine Drugs Share (%), by Country
  • Figure 44. North America Antihistamine Drugs Share (%), by Country
  • Figure 45. Global Antihistamine Drugs: by Type USD/Units (2019-2024)
List of companies from research coverage that are profiled in the study
  • Johnson & Johnson Consumer Inc. (United States)
  • Sanofi (France)
  • Bayer AG (Germany)
  • Pfizer (United States)
  • CVS pharmacy (United States)
  • Merck & Co., Inc. (United States)
  • Prestige Brands Holdings, Inc. (United States)
  • Novartis (Switzerland)
  • Teva Pharmaceutical (Israel)
Additional players considered in the study are as follows:
Boehringer Ingelheim (Germany) , Mylan (United States) , AstraZeneca (United Kingdom)
Select User Access Type

Key Highlights of Report


Dec 2019 210 Pages 75 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Antihistamine Drugs Market Quantitative research analysis
Global Antihistamine Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Antihistamine Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Embolotherapy Comprehensive Study by Type (Embolic Agents, Microspheres, Embolic Coils (Detachable Coils, Pushable Coils), Liquid Embolic Agents, Embolic Plug Systems, Detachable Balloons, Support De...
$ 4800
Plaque Psoriasis Treatment Comprehensive Study by Type (Topical Therapy, Phototherapy, Systemic Agents, Biologic Therapies), Application (Hospitals, Clinics, Others), Drug Class (TNF-α Inhibitor...
$ 3350
Cerebral Infarction Therapy Comprehensive Study by Type (Partial Anterior Circulation Infarct (PACI), Total Anterior Circulation Infarct (TACI), Posterior Circulation Infarct (POCI)), Application (Ho...
$ 3650
Smokeless Tobacco Treatment  Comprehensive Study by Type (Keratosis Treatment, Addiction Treatment, Disease Treatment), Application (Hospitals & Clinics, Academic & Research Organizations, Pharmacies...
$ 3750
Anaplastic Thyroid Cancer Comprehensive Study by Application (Hospitals, Clinics, Ambulatory Surgery Centers), Treatment (Surgery, Radiation Therapy, Chemotherapy, Other), Diagnosis (Imaging (Ultraso...
$ 3350
Behavioral Health Comprehensive Study by Type (Depression, Anxiety, Schizophrenia, Alcohol Use Disorders, Others), Service (Emergency Mental Health Services, Outpatient Counseling, Home-Based Treatme...
$ 3450